Skip to main content
SpringerLink
Log in

Does post-transplant treatment with imatinib mesylate inhibit graft-versus-leukemia?

  • Spotlight Correspondence
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  1. Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004; 18: 1332–1339.

    Article  CAS  Google Scholar 

  2. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S . Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004; 104: 1094–1099.

    Article  CAS  Google Scholar 

  3. Thiede C, Florek M, Bornhauser M, Ritter M, Mohr B, Brendel C et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999; 23: 1055–1060.

    Article  CAS  Google Scholar 

  4. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia 2003; 17: 2318–2357.

    Article  CAS  Google Scholar 

  5. Kim YJ, Kim DW, Lee S, Kim YL, Hwang JY, Park YH et al. Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment. Bone Marrow Transplant 2004; 33: 237–242.

    Article  CAS  Google Scholar 

  6. Shimoni A, Kroger N, Zander AR, Rowe JM, Hardan I, Avigdor A et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 2003; 17: 290–297.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stem Cell Transplant Program – Section of Hematology/Oncology, University of Illinois at Chicago, Chicago, Illinois, USA

    S Chunduri, L C Dobogai & D Rondelli

  2. Department of Pathology, University of Illinois at Chicago, Chicago, Illinois, USA

    A Bruno & S Kadkol

Authors
  1. S Chunduri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L C Dobogai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Bruno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Kadkol
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Rondelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Rondelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chunduri, S., Dobogai, L., Bruno, A. et al. Does post-transplant treatment with imatinib mesylate inhibit graft-versus-leukemia?. Leukemia 19, 456–457 (2005). https://doi.org/10.1038/sj.leu.2403656

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403656

  • Springer Nature Limited

This article is cited by

Search

Navigation